TABLE 2.
Characteristics of HGSOC patient survival based on immune‐specific subtypes
| Immune class | Activated‐immune (A) | CAFs‐immune (C) | Inactivated‐immune (I) | Log‐rank test, Mantel‐Cox P (HR) | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| No. of subjects | N | Dead (%) | Median | N | Dead (%) | Median | N | Dead (%) | Median | A vs. C | A vs. I | C vs. I | |
| Overall | 409 a | 161 | 91 (57) | 36.200 | 84 | 61 (73) | 31.435 | 164 | 103 (63) | 31.475 | 0.014 b (1.5) | 0.15 | 0.19 |
| Age (y) | |||||||||||||
| > 60 | 183 | 64 | 38 (59) | 29.765 | 45 | 37 (82) | 34.760 | 74 | 50 (68) | 25.165 | 0.21 | 0.23 | 0.76 |
| ≤60 | 226 | 97 | 53 (55) | 43.170 | 39 | 24 (62) | 29.070 | 90 | 53 (59) | 37.615 | 0.085 (1.53) | 0.52 | 0.24 |
| Neoplasm grade | |||||||||||||
| G1 + G2 | 48 | 15 | 8 (53) | 40.370 | 14 | 10 (71) | 22.500 | 19 | 14 (74) | 56.500 | 0.046 b (2.61) | 0.69 | 0.14 |
| G3 + G4 | 359 | 145 | 82 (57) | 35.990 | 70 | 50 (71) | 34.360 | 144 | 86 (60) | 27.415 | 0.083 (1.36) | 0.17 | 0.55 |
| Stage | |||||||||||||
| II + III | 345 | 134 | 73 (54) | 36.235 | 72 | 52 (72) | 36.350 | 139 | 85 (61) | 31.180 | 0.027 b (1.49) | 0.088 (1.31) | 0.43 |
| IV | 61 | 25 | 18 (72) | 36.600 | 11 | 8 (73) | 20.660 | 25 | 18 (72) | 32.980 | 0.35 | 0.62 | 0.13 |
| Lymphovascular invasion | |||||||||||||
| No | 55 | 20 | 4 (20) | 29.455 | 7 | 7 (100) | 30.030 | 28 | 14 (50) | 26.875 | 0.0027 c (5.75) | 0.058 (2.84) | 0.44 |
| Yes | 103 | 47 | 27 (57) | 33.440 | 22 | 7 (32) | 20.830 | 34 | 15 (44) | 23.870 | 0.75 | 0.77 | 0.74 |
| Vascular invasion | |||||||||||||
| No | 47 | 19 | 7 (37) | 38.040 | 4 | 3 (75) | 37.060 | 24 | 11 (46) | 21.745 | 0.69 | 0.2 | 0.48 |
| Yes | 64 | 28 | 13 (46) | 38.685 | 16 | 5 (31) | 22.340 | 20 | 8 (40) | 29.865 | 0.9 | 0.75 | 0.87 |
| Residual disease | |||||||||||||
| No macroscopic disease | 73 | 27 | 10 (37) | 41.590 | 7 | 4 (57) | 29.010 | 39 | 16 (41) | 33.940 | 0.49 | 0.91 | 0.63 |
| 1‐20 mm | 219 | 81 | 53 (65) | 36.200 | 52 | 39 (75) | 39.405 | 86 | 60 (70) | 29.125 | 0.22 | 0.12 | 0.82 |
| >20 mm | 74 | 30 | 21 (70) | 28.615 | 19 | 16 (84) | 19.450 | 25 | 17 (68) | 28.350 | 0.42 | 0.7 | 0.12 |
| Primary tumour site | |||||||||||||
| Left | 54 | 29 | 13 (45) | 41.950 | 8 | 6 (75) | 37.695 | 17 | 12 (71) | 39.060 | 0.06 (2.57) | 0.29 | 0.28 |
| Right | 45 | 18 | 11 (61) | 17.360 | 6 | 5 (83) | 31.360 | 21 | 11 (52) | 25.360 | 0.63 | 0.36 | 0.56 |
| Bilateral | 286 | 107 | 64 (60) | 36.330 | 62 | 44 (71) | 33.180 | 117 | 74 (63) | 31.180 | 0.11 | 0.24 | 0.57 |
| Platinum status | |||||||||||||
| Sensitive | 163 | 65 | 31 (48) | 49.640 | 31 | 20 (65) | 44.970 | 67 | 44 (66) | 43.890 | 0.26 | 0.077 (1.51) | 0.69 |
| Resistant | 70 | 25 | 21 (84) | 29.400 | 14 | 13 (93) | 22.435 | 31 | 28 (90) | 33.900 | 0.85 | 0.28 | 0.55 |
a
Two cases with NA (not available) clinical record.
b
< 0.05.
c
< 0.01, significant, based on log‐rank test P values.